Vetr downgraded shares of Illumina, Inc. (NASDAQ:ILMN) from a buy rating to a sell rating in a research report report published on Tuesday. They currently have $157.22 price objective on the life sciences company’s stock.
Other equities research analysts have also recently issued research reports about the stock. Argus reissued a buy rating and set a $170.00 target price (down previously from $205.00) on shares of Illumina in a research report on Friday, October 14th. Citigroup Inc. increased their target price on shares of Illumina from $175.00 to $190.00 and gave the company a buy rating in a research report on Monday, September 12th. CL King raised shares of Illumina from a neutral rating to a buy rating in a research report on Friday, January 6th. Bank of America Corporation raised shares of Illumina from a neutral rating to a buy rating and increased their target price for the company from $145.00 to $175.00 in a research report on Tuesday. Finally, Barclays PLC set a $142.00 target price on shares of Illumina and gave the company an equal weight rating in a research report on Tuesday, October 11th. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eight have given a buy rating to the company’s stock. Illumina presently has an average rating of Hold and a consensus price target of $152.67.
Illumina (NASDAQ:ILMN) traded down 1.34% during midday trading on Tuesday, reaching $162.83. 1,961,900 shares of the company’s stock were exchanged. Illumina has a 12-month low of $119.37 and a 12-month high of $186.88. The stock’s 50-day moving average is $130.13 and its 200-day moving average is $150.44. The stock has a market capitalization of $23.92 billion, a price-to-earnings ratio of 54.64 and a beta of 1.16.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, November 1st. The life sciences company reported $0.97 EPS for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.10. Illumina had a net margin of 18.72% and a return on equity of 23.76%. The company earned $607 million during the quarter, compared to analysts’ expectations of $628.06 million. During the same quarter in the prior year, the company posted $0.80 earnings per share. Illumina’s revenue for the quarter was up 10.4% compared to the same quarter last year. On average, equities analysts forecast that Illumina will post $3.32 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/01/11/illumina-inc-ilmn-lowered-to-sell-at-vetr-inc.html.
In other news, Director Daniel Bradbury sold 600 shares of the company’s stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $135.01, for a total transaction of $81,006.00. Following the transaction, the director now directly owns 17,065 shares of the company’s stock, valued at approximately $2,303,945.65. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Omead Ostadan sold 3,000 shares of the company’s stock in a transaction on Thursday, December 8th. The stock was sold at an average price of $121.63, for a total transaction of $364,890.00. Following the transaction, the executive vice president now directly owns 52,988 shares in the company, valued at $6,444,930.44. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.
Several institutional investors have recently bought and sold shares of ILMN. Capital Research Global Investors boosted its position in Illumina by 17.1% in the second quarter. Capital Research Global Investors now owns 13,085,071 shares of the life sciences company’s stock worth $1,836,882,000 after buying an additional 1,910,346 shares during the period. Capital World Investors boosted its stake in shares of Illumina by 218.0% in the second quarter. Capital World Investors now owns 1,463,000 shares of the life sciences company’s stock worth $205,376,000 after buying an additional 1,003,000 shares during the last quarter. Baillie Gifford & Co. boosted its stake in shares of Illumina by 3.8% in the second quarter. Baillie Gifford & Co. now owns 18,615,061 shares of the life sciences company’s stock worth $2,613,182,000 after buying an additional 682,010 shares during the last quarter. American Capital Management Inc. acquired a new stake in shares of Illumina during the third quarter worth approximately $43,373,000. Finally, Vanguard Group Inc. boosted its stake in shares of Illumina by 2.0% in the second quarter. Vanguard Group Inc. now owns 8,982,784 shares of the life sciences company’s stock worth $1,261,004,000 after buying an additional 178,186 shares during the last quarter. 92.94% of the stock is currently owned by institutional investors and hedge funds.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.